Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532908 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
A Phase 2 study, sponsored by MassBiologics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01532908 is a Phase 2 study that was terminated before completion, run by MassBiologics. The registered enrollment target is 11 participants.
The verdict
NCT01532908, a Phase 2 study, was terminated before completion, sponsored by MassBiologics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy of a human monoclonal antibody against Hepatitis C (MBL-HCV1) combined with telaprevir \[part 1: an HCV protease inhibitor\] or sofosbuvir \[part 2: an Hepatitis C virus NS5B polymerase inhibitor\] in a 56 day treatment duration in patients undergoing liver transplantation due to chronic HCV infection. There is an option for extended study treatment through 84 days if viral load is undetectable at day 56.
Interventions
- BIOLOGICAL MBL-HCV1
- DRUG Telaprevir (Part 1)
- DRUG Sofosbuvir (Part 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-11-21 |
| Est. Completion | 2015-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532908
The ClinicalTrials.gov registry entry for NCT01532908 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MassBiologics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MBL-HCV1 is the first listed.
NCT01532908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532908 about?
NCT01532908 is a clinical study titled "Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C". The purpose of this study is to assess efficacy of a human monoclonal antibody against Hepatitis C (MBL-HCV1) combined with telaprevir \[part 1: an HCV protease inhibitor\] or sofosbuvir \[part 2: an Hepatitis C virus NS5B polymerase inhibitor\] in a 56 day treatment duration in patients undergoing ...
What is the current status of trial NCT01532908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2012-11-21. Estimated completion is 2015-08-27.
What interventions are being tested in trial NCT01532908?
The interventions under investigation include: MBL-HCV1 (BIOLOGICAL), Telaprevir (Part 1) (DRUG), Sofosbuvir (Part 2) (DRUG).
Who is sponsoring clinical trial NCT01532908?
This trial is sponsored by MassBiologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.